Mounting research suggests that short protein therapies represent a exciting emerging area for malignant management. Unlike traditional drug therapy, these treatments can be engineered to specifically attack tumor tissue while limiting damage to normal tissue. This specificity holds the potential for improved outcomes and fewer adverse reactions f